This study was set out to determine the function of LAMC2 in laryngeal cancer (LC). Initially, we identified the expression of LAMC2 in LC cells and tissues using TCGA datasets, GEO datasets (GSE143224), qRT-PCR, and western blot. Besides, we analyzed the correlations between LAMC2 and clinicopathologic features in LC patients. The CCK-8 assays were performed to detect cell viability and the half-maximal inhibitory concentration of cetuximab (IC50) in LC cells. We explored the correlations between LAMC2 and EGFR and further explored the regulation mechanism of cetuximab in LC. This study identified a high expression of LAMC2 in LC cells and tissues. The expression levels of LAMC2 were associated with TNM classification, lymph node (LN) metastasis, differentiation, and overall survival (OS). LAMC2 significantly promoted cell proliferation and cell viability. Besides, cetuximab significantly inhibited LAMC2 expression levels. LAMC2 significantly reversed the effect of cetuximab suppressing cell proliferation in LC cells. In conclusion, LAMC2 may act as a novel anti-cancer target in LC.

中文翻译：

---

LAMC2 作为西妥昔单抗治疗喉癌的新靶点。

本研究旨在确定 LAMC2 在喉癌 (LC) 中的功能。最初，我们使用 TCGA 数据集、GEO 数据集 (GSE143224)、qRT-PCR 和蛋白质印迹鉴定了 LC 细胞和组织中 LAMC2 的表达。此外，我们分析了 LAMC2 与 LC 患者临床病理特征之间的相关性。进行 CCK-8 测定以检测 LC 细胞中的细胞活力和西妥昔单抗 (IC50) 的半数最大抑制浓度。我们探讨了 LAMC2 与 EGFR 之间的相关性，并进一步探讨了西妥昔单抗在 LC 中的调节机制。该研究确定了 LAMC2 在 LC 细胞和组织中的高表达。LAMC2 的表达水平与 TNM 分类、淋巴结 (LN) 转移、分化和总生存期 (OS) 相关。LAMC2显着促进细胞增殖和细胞活力。此外，西妥昔单抗显着抑制 LAMC2 表达水平。LAMC2 显着逆转了西妥昔单抗抑制 LC 细胞增殖的作用。总之，LAMC2 可作为 LC 中的新型抗癌靶点。